The Intact Non-Inducible Latent HIV-1 Reservoir is Established In an In Vitro Primary T\textsubscript{CM} Cell Model of Latency

Indra Sarabia\textsuperscript{1}, Szu-Han Huang\textsuperscript{2}, Adam R. Ward\textsuperscript{1,2}, R. Brad Jones\textsuperscript{1,2} and Alberto Bosque\textsuperscript{1#}

\textsuperscript{1}Department of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, USA.

\textsuperscript{2}Infectious Disease Division, Weill Cornell Medical College, New York, USA.

Running Head: Intact non-inducible latent HIV in primary CD4 T cells

# Address correspondence to Alberto Bosque, abosque@gwu.edu
Abstract: The establishment of HIV-1 latency has hindered an HIV-1 cure. “Shock and Kill” strategies to target this reservoir aim to induce the latent provirus with latency reversing agents (LRAs). However, recent studies have shown that the majority of the intact HIV-1 viral reservoir found in ART-suppressed HIV infected individuals is not inducible. We sought to understand whether this non-inducible reservoir is established, and thus able to be studied, in an in vitro primary T_{CM} model of latency. Furthermore, we wanted to expand this model system to include R5-tropic and non-B subtype viruses. To that end, we generated our T_{CM} model of latency with an R5 subtype B virus, AD8 and an R5 subtype C virus, MJ4. Our results demonstrate that both intact and defective proviruses are generated in this model. Less than 50% of intact proviruses are inducible regardless of viral strain in the context of maximal stimulation through the TCR or with different clinically relevant LRAs including the HDAC inhibitors SAHA and MS-275, the PKC agonist Ingenol 3,20-dibenzoate or the SMAC mimic AZD-5582. Our findings suggest that current LRA strategies are insufficient to effectively reactivate intact latent HIV-1 proviruses in primary CD4 T_{CM} cells and that the mechanisms involved in the generation of the non-inducible HIV-1 reservoir can be studied using this primary in vitro model.

Importance: HIV-1 establishes a latent reservoir that persists under antiretroviral therapy. Antiretroviral therapy is able to stop the spread of the virus and the progression of the disease but does not target this latent reservoir. If antiretroviral therapy is stopped, the virus is able to resume replication and the disease progresses. Recently, it has been demonstrated that most of the latent reservoir capable of generating replication competent virus cannot be induced in the laboratory setting. However, the mechanisms that influence the generation of this intact and non-inducible latent reservoir are still under investigation. Here we demonstrate the generation of defective,
intact and intact non-inducible latent HIV-1 in a $T_{CM}$ model of latency using different HIV-1 strains. Thus, the mechanisms which control inducibility can be studied using this primary cell model of latency, which may accelerate our understanding of the latent reservoir and the development of curative strategies.
INTRODUCTION

Human immunodeficiency virus-1 (HIV-1) persists during antiretroviral therapy (ART) due to a pool of latently infected cells. ART greatly improves outcomes for people living with HIV-1 (PLWH), but it does not target latently infected cells, so it cannot cure HIV-1 (1-3). It is known that these cells are largely comprised of resting memory CD4 T cells, though other CD4 subsets and other cell types can also contribute to the latent reservoir (4-9). One current strategy towards an HIV-1 cure is “Shock and Kill,” where the latent virus is induced using small molecules and subsequently eliminated due to immune clearance or viral cytopathicity (for reviews, see: (10-12)). In order to develop successful interventions, the basic mechanisms underlying latency establishment and reversal must be known. Mechanistic studies are difficult to carry out in samples from PLWH due to the availability of sample and the scarcity of these cells in vivo; thus, cell lines and primary cell models serve an important purpose in understanding the biology of HIV-1 latency. Our group has extensively characterized a primary T<sub>CM</sub> model of latency that utilizes the replication competent molecular clone NL4-3, a subtype B CXCR4 (X4)-tropic virus. This model has been extensively used to discover and evaluate latency-reversing agents (LRAs); to perform mechanistic studies examining pathways involved in the establishment and maintenance of latency; and has been extensively compared with latent cells isolated from PLWH including integration site analysis, clonal expansion and blocks in HIV-1 splicing (13-29).

Worldwide, the majority of HIV-1 infections are subtype C, and subtype B accounts for a little over ~10% of total HIV-1 infections (30). Recent studies have highlighted differences in reservoir size among individuals with different subtypes (31, 32). Omondi et al found that subtype-specific Nef function correlated with reservoir size, but it did not fully explain the
differences observed (32). Currently, it is unclear if subtype also plays a role in the establishment of latency or its reversal (for a review, see (33)). Further, Pierson and colleagues showed that the majority of viruses in the latent reservoir utilize CCR5 (R5) for entry, though some CXCR4 usage was also observed (34). Thus, we wanted to test whether this latency model could be generated using R5-tropic viruses (including a subtype C virus), which may be more biologically relevant to the generation of the latent reservoir and would allow for inclusion of more diverse viruses in HIV-1 cure research using this primary cell model.

Here, we describe such efforts to expand this latency model, thus enhancing its utility for the development of cure strategies and understanding the mechanism underlying HIV-1 latency. To that end, we characterized the proportions of intact and defective latent proviruses generated in this model with three replication competent HIV-1 molecular clones and evaluated clinically relevant LRAs in their ability to reactivate latent and intact HIV-1.

**Results**

*R5 and subtype C viruses generate latency in the T_CCM model of latency*

To expand this latency model to include an R5 or a non-B subtype virus, we chose the R5 subtype B virus AD8 (35) and the R5 subtype C virus MJ4 (36) to generate latently infected cells using the cultured T_CCM model, as outlined in Figure 1A (18, 19). Expanded naïve CD4 T cells were spin-infected with either AD8, MJ4, or NL4-3 at a low multiplicity of infection. We measured productive infection *in vitro* on day 10 using flow cytometry by staining for intracellular p24-Gag expression and surface CD4 down-regulation (Figure 1B, Day 10, and 1C). We then “crowded” the cells to facilitate cell-to-cell spread of infection (Figure 1B, Day 13, and 1C). We consistently observed an increase in infection from day 10 to day 13, across multiple donors, showing that the R5 viruses AD8 and MJ4 were able to infect and replicate *in vitro* in
this model (Figure 1C). There were significant differences in replication rates (change in
infection from day 10 to day 13) between AD8 and NL4-3 and between AD8 and MJ4, where
AD8 had the lowest replication rate (Figure 1D). After uncrowding, cells were cultured in the
presence of AMD-3100, Efavirenz, and Nelfinavir to stop the spread of infection for an
additional 4 days. We previously published this model using Raltegravir and Nelfinavir, but
eliminated the integrase inhibitor Raltegravir from our culturing conditions to reduce 2-LTR
circle accumulation in this model of latency (24). After 4 days in culture with antiretroviral drugs
(ARVs), productively infected cells decreased for AD8 and NL4-3 (Figure 1B, Day 17 Pre-sort,
1C, and 1E). We did observe a greater percentage of MJ4-infected cells remained in culture after
ARV introduction. The new combination of ARVs is equally effective at suppressing viral
replication as the original combination of Raltegravir and Nelfinavir for all strains, indicating
that the remaining HIV-1 infected cells was not due to ongoing replication (Figure 1F).
Currently, there is no biomarker for viral latency, so we enriched for latently infected cells by
eliminating the productively infected cells from culture. To do this, cells were magnetically
sorted based on CD4 expression on day 17, which eliminated productively infected cells
measured as p24 positive CD4 negative (Figure 1B, Day 17 Post-sort). CD4 expression is
downregulated on the cell surface due to the expression of the accessory genes Nef and Vpu (37,
38). This procedure leaves only uninfected and latently infected cells (19). We eliminated
productively infected cells to assess de novo reactivation from latency without the confounding
variable of ongoing viral replication. To reactivate latent proviruses, cells were either stimulated
with ARVs and IL-2/CD3/CD28, which mimics T cell activation, or ARV-containing media
control for 48 hours. All viruses established latency and were reactivated; AD8 exhibited the
lowest percentage of reactivated cells when stimulated with IL-2/CD3/CD28, followed by MJ4,
then NL4-3 (Figure 1G). In this model of latency, we had previously observed that the degree of infection on day 13 was correlated with the degree of reactivation seen on day 19 with CD3/CD28 beads (18). Indeed, here we observed a correlation between infection at day 13 and reactivation on day 19 with all viruses used (Figure 1H). Our measure of viral reactivation, p24-Gag expression and CD4-downregulation by flow cytometry, takes into account transcription, splicing, and translation of viral proteins but does not reveal the total size of the pool of latently infected cells able to be reactivated, thus, raising the question of whether all possible proviruses are successfully reactivated in this in vitro model. To address this question, we used measurement of proviral DNA to estimate the pool of potentially inducible latently infected cells.

**Low inducibility of latent HIV-1 despite maximal stimulation**

After sorting based on CD4 expression at day 17 and prior to viral reactivation, DNA was isolated and total HIV-1 gag copies quantified using digital droplet PCR (ddPCR). Gag copies were normalized to million T_CM cells by measuring copies of RPP30 by ddPCR. AD8 had the lowest copies of HIV-1 gag, followed by MJ4 and then NL4-3 (Figure 2A). After normalizing the viral reactivation shown in Figure 1G to total HIV-1 gag copies, we still observed a statistically significant reactivation from latency with IL-2/CD3/CD28 stimulation for all viruses (Figure 2B). Interestingly, we observed that IL-2/CD3/CD28 stimulation induced less than 7% of total HIV-1 gag copies regardless of viral strain. There were no significant differences in reactivation between any of the viruses (Figure 2C). It has been previously shown that the majority of proviruses are defective in CD4 T cells isolated from PLWH on long-term ART (39). It is possible that we observed low inducibility as a result of normalizing to total HIV-1 gag copies, many of which could be defective, thus overestimating the pool of potentially inducible
To address this concern, we characterized the composition of intact versus defective proviruses in this in vitro model, in order to normalize reactivation to copies of intact proviruses. We used a modified version of the intact proviral DNA assay (IPDA) to determine whether proviruses were intact or deleted/mutated (41). We observed the same patterns as with total HIV-1 gag copies, where AD8 had the fewest intact proviral DNA copies, followed by MJ4 and then NL4-3 (Figure 2D). We observed the same patterns of inducibility when normalized to total intact proviral DNA copies instead of total HIV-1 gag copies (Figure 2E) and did not observe a significant difference between viruses (Figure 2F). Despite the short culture time, 47-58% of proviruses were intact and 43-53% of proviruses were defective in the 5’ or 3’ region of the HIV-1 genome (Figure 2G), the majority of them being 5’ deletions. In a subset of donors, we observed that most of 3’ defective viruses were due to deletions and not hypermutations (Figure 2H). The DNA shearing index (DSI) used to account for shearing in the IPDA is shown in Figure 2I and is similar to what has been previously published (41). In this model, the copies of intact proviruses and total HIV-1 gag copies are correlated for all viruses used (Figure 2J).

**LRAs are ineffective at inducing the majority of intact latent proviruses**

We next addressed LRA activity in this latent cell model generated with the 3 distinct HIV-1 viruses. We selected a panel of LRAs from three distinct classes: the PKC agonist Ingenol 3,20-dibenozoate (Ingenol) (42, 43), HDAC inhibitors (HDACi) SAHA and MS-275 (44-48), and the SMAC mimetic AZD-5582 (49, 50). At day 17, sorted latently infected cells were stimulated with LRAs for 48 hours with the exception of AZD-5582, which was added for 1 hour and then washed out (49, 50). We chose these timepoints to assess the efficacy of reactivation and compare to previously published works that have characterized the LRA activity of these...
compounds at this timepoint (42, 43, 48, 49). IL-2 alone was sufficient to reactivate MJ4 and
NL4-3 latently infected cells (Figure 3A). Ingenol and AZD-5582 activate the canonical and
non-canonical Nuclear Factor kappa light chain enhancer of activated B cells (NF-κB) signaling
pathway, respectively. Ingenol significantly reactivated AD8 and NL4-3 latently infected cells
but was not significantly different than the IL-2 control for MJ4 (Figure 3A). AZD-5582
reactivated latent HIV-1 though it did not reactivate more than CD3/CD28 in 3/6 (AD8), 3/7
(MJ4) and 3/6 (NL4-3) latently infected donors (Figure 3A). HDACi reduced the ability of IL-2
to reactivate latent HIV-1 in this model of latency. We next wanted to assess how effective these
LRAs were at inducing the intact latent reservoir, so we normalized the data to intact copies of
HIV-1 (Figure 3B). The mean percentage of inducible intact proviruses by each individual LRA
was less than 3%, while 97% of the intact latent reservoir was unperturbed in this model of
latency; no single LRA reactivated more than CD3/CD28 stimulation. We observed minor
differences between viruses with respect to sensitivity to the three distinct classes of LRAs.

The intact, integrated, inducible reservoir in the TCM model of latency

Although our culturing conditions did not contain Raltegravir which could cause an
accumulation of 2-LTR circles, we determined whether the intact copies measured by ddPCR
were also integrated. Linear and unintegrated HIV-1 DNA could potentially be a bias in primary
cell models of latency. We used Pulsed Field Gel Electrophoresis (PFGE) to remove
unintegrated HIV-1 DNA from a portion of our samples. PFGE has been shown to effectively
eliminate unintegrated HIV-1 DNA and is correlated with Alu-PCR (51, 52), the gold standard
for measuring integrated HIV-1 DNA. We confirmed that PFGE removed 2-LTR circles (Figure
4A) as previously reported (51, 52). We then repeated the IPDA and measured the number of
total (sum of intact and defective proviruses) and intact copies after PFGE (Figure 4B). The percentage of total copies that remained after PFGE were as follows: AD8 had an average of 6% +/- 2.1%, MJ4 had an average of 6.1% +/- 3.3% and NL4-3 3.6% +/- 1%. For the percentage of intact copies that remained after PFGE: AD8 had on average 6.4 +/- 4.9%, MJ4 had 6.1% +/- 2.8%, and NL4-3 had 3.1% +/- 1.1%. With all three viruses, overall, 5.5% +/- 3.5% of the intact copies remained after PFGE, and 5.4% +/- 2.6% of total copies remained after PFGE. After PFGE, AD8 had the smallest percentage of intact copies and similar proportions of 5’ deleted and 3’deleted/hypermutated copies (Figure 4C). MJ4 had the greatest proportion of intact proviruses, with similar distributions of defective proviruses (Figure 4D). Interestingly, NL4-3 had similar levels of intact proviruses as AD8 but had more 3’ deleted/hypermutated copies than 5’ deleted copies (Figure 4E). We found a correlation between total copies (Figure 4F) as well as intact copies (Figure 4G) of HIV-1 pre- and post-PFGE. Similar to our previous data with total HIV-1 Gag copies, we also observed a correlation between infection at day 13 and total HIV copies (Figure 4H) and intact copies (Figure 4I) post-PFGE. In our post-PFGE samples, we also observed a correlation between reactivation seen with CD3/CD28 stimulation on day 19 and total HIV-1 copies (Figure 4J) and intact HIV-1 DNA copies (Figure 4K). When reactivation was normalized to total integrated proviruses, we observed that an average of 30% of the latent reservoir generated in this latency model was induced with CD3/CD28 stimulation (Figure 5A), and an average of 50% reactivation when normalized to integrated intact copies (Figure 5B). We observed similar patterns of reactivation with LRAs as before, but the magnitude of induction was greater. No single LRA exceeded the reactivation induced by CD3/CD28, though Ingenol and AZD-5582 (in a subset of donors) were the most potent of the clinically relevant LRAs tested (Figure 5C).
Discussion

In vitro latency models are important tools in the development of HIV-1 cure strategies. Prior to this study, the T<sub>CM</sub> latency model had been generated only with CXCR4-tropic subtype B viruses. The majority of viruses in the latent reservoir utilize CCR5 for entry (34), providing strong rationale to generate this model using R5 viruses. Our data shows that this model can generate a heterogenous latent reservoir in vitro, which harbors intact, integrated, inducible and uninducible latent proviruses with an R5 or subtype C virus. AD8 is a virus with an R5 primary isolate envelope (from HIV-1 ADA derivative AD8.1), with the backbone of NL4-3 (35). During the generation of these latently infected cells, we observed differences in infection between AD8 and NL4-3, likely due to differences in infection efficiency between virus envelopes (53, 54) and/or less CCR5 expression than CXCR4 in this model (14). As both R5 viruses infected, replicated, and established latency in this model, it is a proof of concept that using more diverse R5-tropic viruses is possible within this system. Further, we recently showed that this model allows the generation of latently infected cells using primary viruses isolated from ART-suppressed PLWH using the quantitative viral outgrowth assay (QVOA) (26).

Interestingly, in this model almost half of proviruses are defective despite a short replication time (7 days). Defective proviruses are most abundant in CD4 T cells isolated from PLWH on long-term ART (39, 52, 55, 56). Specifically, in the T<sub>CM</sub> subset, 3’ deletions/ hypermutations are most abundant, followed by 5’ deletions, and lastly intact copies (41). This is in contrast to our in vitro model, which had on average ~50% of intact proviruses, followed by similar proportions of 3’deleted/hypermutated and 5’ deleted proviruses across all viruses used. However, our results are in line with previous observations on intact proviruses generated in vitro. Pinzone and
collaborators characterized intact and defective provirus kinetics in their *in vitro* model and found that resting cells accumulated more defective proviral forms, but in their single round of infection, the majority of copies were intact (52). In our latency model, we infect cells 7 days after activation as they are transitioning into a more resting phenotype, which may explain why we observe defective forms and why a much larger portion of latent proviruses are intact than in CD4 T cells isolated from PLWH on long-term ART. Additionally, the composition of intact and defective proviruses may be affected by the short culturing timeframe, the lack of selection due to immunological responses to defective viruses (57), or shorter period of infection, thus explaining the minor proportion of APOBEC3G-induced mutations or deletions (58-60). With regard to proportions of intact proviruses between the three viruses tested, we observed a trend where MJ4 generated the most intact proviruses (post-PFGE). However, further work with other subtype C clones or primary viral isolates is needed to determine whether this is intrinsic to that particular HIV-1 molecular clone or whether it is subtype-specific. We observed that in some donors we measured over one copy of HIV-1 per cell when measuring total HIV Gag, suggesting multiple proviruses per cell or unintegrated forms present in the sample. Indeed, after PFGE we found that 91 to 97% of those copies detected were unintegrated, but the majority of unintegrated forms were not explained by 2-LTR circles alone, as they represent ~0.2% of copies in a representative sample pre-PFGE (Figure 4A). This proportion of integrated copies is consistent with a previous study where approximately only 10% of HIV-1 DNA copies were detected using Alu-PCR (61). Future work in this *in vitro* model will need to eliminate unintegrated HIV-1 copies before drawing conclusions on provirus inducibility, reduction of the latent reservoir or infection frequency using any DNA-based measurement.
Due to donor-to-donor variation, it is not possible to get the same degree of latent infection each iteration of the model. As such, HIV-1 DNA measurements are required to estimate the pool of latently infected cells. Total HIV-1 Gag or total intact copies could overestimate the size of the latent reservoir unless non-integrated forms are eliminated. Once reactivation was normalized to post-PFGE intact copies, we observed that an average of 50% of intact integrated proviruses were induced with CD3/CD28. This is in contrast to the low inducibility observed in CD4 T cells isolated from PLWH on long-term ART (41), likely due to the stark differences in proportions of intact proviruses between the two types of samples, selection of noninducible proviruses over time in PLWH, or cell-intrinsic differences. Interestingly, in a subset of donors the percent inducibility is over 100% with CD3/CD28 stimulation. This is a potential caveat of the study, since it could mean that there are somehow more reactivated cells than infected cells. One possible explanation is that some defective proviruses may still be able to express Nef and Gag proteins (56), and are captured in our p24-CD4 flow assay. Indeed, when we normalize to total (the sum of intact, 5′ defective, and 3′defective/hypermutated copies) post-PFGE HIV-1 copies, we do not observe any donors above 100% inducibility. Since it is not possible to simultaneously distinguish which cells reactivated because of reactivation of an intact latent provirus vs a defective latent provirus, an additional measurement of viral release or viral outgrowth after stimulation may be helpful in determining inducibility more accurately.

With that caveat in mind, the LRAs assessed in this work were not more effective than CD3/CD28 stimulation, which mainly triggers Nuclear Factor of Activated T cells (NFAT) in this model (14). Of the LRAs tested, Ingenol 3,20 dibenzoate and AZD-5582 came closest in activity CD3/CD28 (Figure 5C). Ingenol 3,20 dibenzoate triggers the canonical NF-κB pathway (42), while AZD-5582 triggers the non-canonical NF-κB pathway (49). We observed better
reactivation of MJ4-latently infected cells to AZD-5582 than other classes of LRAs tested when comparing to AD8 or NL4-3 in magnitude of reactivation. This could be due to subtype specific factors. Subtype C LTR can harbor up to 3 NF-κB binding sites, instead of two found in subtype B, that could explain a higher response to certain stimuli that activate NF-κB (33). However, further work needs to be done with other subtype C clones or primary viral isolates to determine whether this is intrinsic to that particular HIV-1 molecular clone or whether it is subtype-specific. Previous work in cell lines has shown that additional NF-κB sites lead to enhanced transcriptional activity (62, 63), but this has not been evaluated in primary cell models with replication competent viruses. We did not observe LRA activity with SAHA. This may be explained because we measure viral protein expression upon reactivation, and previous works describing these LRAs have measured mostly viral RNA production (46, 47, 64). MS-275 did not have activity in reactivating latent HIV-1 in our latency model either. Taken together, these data show that current LRAs do not reactivate the majority of the latent reservoir generated in this system and would likely be ineffective for HIV-1 cure strategies as single agents.

Our study is not without caveats: this in vitro model is a TCM-based model of latency and thus cannot recapitulate how other T cell subsets or cell types of the latent reservoir may behave. Although it has been previously shown that distinct CD4 T cell subsets have differing degrees of sensitivity to latency reversal (65-67), recent work by Kwon et al has shown that intact proviruses are distributed evenly among the CD4 T cell subsets, and are similarly poorly inducible (68). This in vitro system was designed to mimic latently infected TCM cells from blood, which are a suitable proxy for reservoir measurement in secondary lymphoid organs such as lymph nodes (69). It is important to note that this model only uses CD4 T cells, and as such this model cannot recapitulate immune selective pressures on the virus that occur in vivo (57).
In spite of these caveats, this model has several similitudes when compared with the reservoir in PLWH. First, as we show in this work, this model generates defective and intact proviruses, some of which are not induced with maximal stimulation in vitro similar to that found CD4 T cells isolated from PLWH on long-term ART. Second, this model recapitulates similar integration patterns, including the generation of expanded sites (23). Third, this model recapitulates the blocks to transcription initiation, multiple splicing, and potentially elongation that is observed in CD4 T cells isolated from PLWH on long-term ART (26). These similarities are likely due to the use of replication competent viruses and primary cells, as their metabolism and abundance of host factors better mirrors primary CD4 T cells compared to tumoral cell lines.

The main conclusions from this study are that the T<sub>CM</sub> latency model can indeed be expanded to use R5 and non-subtype B virus strains increasing the utility of this model for HIV-1 cure strategies as the majority of the worldwide HIV-1 infections are non-B (30). This model also generates a heterogenous reservoir, with intact and defective proviruses despite a short culturing time as well as recapitulates the generation of intact non-induced proviruses. As such, this model could be used to further understand the mechanisms involved in HIV persistence in CD4 T cells as well as the pre-clinical evaluation of HIV cure strategies.

**Materials and Methods**

**Reagents**

The following reagents were obtained from the NIH AIDS Research and Reference Reagent program, Division of AIDS, NIAID: Nelfinavir, AMD-3100, Efavirenz. HIV-1<sub>NL4-3</sub> was obtained from Dr. Malcom Martin (Cat# 114) (70). HIV-1 NL4-3<sub>AD8</sub> Infectious Molecular Clone (pNL(AD8)) was obtained from Dr. Eric O. Freed (cat# 11346) (35). HIV-1<sub>MJ4</sub> Infectious Molecular Clone (pMJ4) from Drs. Thumbi Ndung’u, Boris Renjifo and Max Essex (cat#6439)
Recombinant IL-2 was obtained from the NCI Pre-clinical repository. SAHA and MS-275 were obtained from Cayman Chemical. AZD-5582 was obtained from Selleck Chem. Ingenol 3,20 Dibenzoate was obtained from Enzo Life Sciences. αCD3/αCD28-coated beads (“Dynabeads”) were obtained from Invitrogen.

**Generation of latently infected TCM cells**

Latently infected cells were generated as previously described (14, 15, 18, 19). Both male and female blood donors were used in the generation of latently infected cells as previously shown (13-15, 18, 19) with some modifications. Briefly, naïve CD4 T cells were isolated from HIV-1-negative blood donors using magnetic isolation (Sepmate™ Primary Human CD4 T cell isolation kit, STEMCELL Technologies). Naïve CD4 T cells were activated with αCD3/αCD28 Dynabeads (1:1 ratio of cells to beads) in the presence of anti-human IL-4, anti-human IL-12, and TGF-β1 (1µg/mL, 2µg/mL, and 10ng/mL respectively, from Peprotech). Cells were plated in 96-well round bottom plates at a density of 0.5x10^6 cells/mL in RPMI supplemented with 10% FBS, penicillin/streptomycin and L-glutamine (complete RPMI) for 3 days. Afterwards, αCD3/CD28 beads were removed using the Dynal MPC-L magnetic particle concentrator (Invitrogen). Cells were resuspended and kept at a cell density of 1x10^6 cells/mL in complete RPMI with 30 IU/mL IL-2. Media was replaced on days 4 and 5 of culture. To generate latently infected cells, cells were infected on day 7 of culture using NL-AD8 (referred to here as AD8) and MJ4 were used in addition to NL4-3. One fifth of the culture was kept uninfected in complete media with IL-2, and one fifth of the cells was infected with either AD8, MJ4, or NL4-3 by spinoculation at 2,900 rpm for 2 hours at 37°C. The amount of virus used to infect was determined by titrating in day 7 primary CD4 T cells to achieve around 3-5% infection at day 10. After spinoculation, infected
cells were added to the remaining three-fifths culture with complete media and IL-2. At day 10, cells were plated in 96-well round bottom plates in complete media with 30 IU/mL IL-2 to facilitate cell-to-cell spread of infection (“crowding” phase). At day 13, cells were transferred to flasks and the following antiretroviral drugs were added to both infected and uninfected cultures to stop further infection at the following concentrations: 0.5µM Nelfinavir, 100nM Efavirenz and 100nM AMD-3100. At day 17, infected and uninfected cells were sorted using a CD4-positive isolation kit (Dynabeads CD4 Positive Isolation Kit, Invitrogen 11331D) to isolate the latently infected cell population. The isolation was carried out as indicated in the manufacturer protocol with two modifications: 1) the amount of CD4 beads was increased threefold and 2) the resuspension volume of buffer II was changed to 200-300µL per 10⁷ cells.

Isolation of high molecular weight DNA using PFGE

Genomic DNA was extracted using the DNeasy Blood and Tissue kit (Qiagen) according to manufacturer’s protocol from a minimum of 1x10⁶ day 17 CD4-sorted latently infected cells. A portion of the isolated genomic DNA was set aside for ddPCR assays described below, while the remaining genomic DNA was subjected to Pulsed-Field Gel Electrophoresis. High molecular weight DNA (which is enriched for integrated HIV-1 DNA) was isolated using the BluePippin platform (Sage Science), as previously described (51, 52) with one modification: the cut-off for DNA collection was lowered to 10kb to improve DNA yield. Purified high molecular weight DNA was then used for ddPCR assays to determine intact, integrated proviruses.

Digital droplet polymerase chain reaction (ddPCR)
Genomic DNA from day 17 latently infected cells was isolated as described above. For each PCR reaction, 50 ng fragmented using QiaShredder columns (Qiagen) or up to 50 ng of purified HMW DNA was used directly. DNA was added to ddPCR Supermix for probes (Biorad) with 900 nM final concentration of primers and 250 nM final concentration of probes. Droplets were generated using the QX100 droplet generator (Biorad). For total gag HIV-1 copies, plates were cycled as previously described (71) and read on a QX100 Droplet Reader (Biorad). Most primers and probes were previously published (71), but those generated in this work are listed in Table 1. The IPDA was performed as previously described with previously published primers (41), with a few modifications. The thermal cycling parameters are as follows: 95°C for 10 minutes for 1 cycle, then 94°C for 30 seconds and 53°C for 1 minute for 40 cycles, followed by 98°C for 10 minutes for 1 cycle, kept at 12°C until reading. The DNA shearing index was calculated and applied to the copies of intact and hypermutated or deleted proviruses as previously described (41). For subtype C samples, primers and probes were designed to span the same packaging signal and envelope regions as the subtype B IPDA primers (Table 1). RPP30 was used to normalize gag or intact proviral DNA copies to cell numbers. To distinguish between 3’ deletions or hypermutations, a modified IPDA was performed by using the envelope primers and probe with a fluorescent hypermutation probe in the same reaction.

**Reactivation assays**

For latency reversal assays, 1-3x10^5 latently infected cells (Day 17, CD4 sorted) were plated in ARV-containing media (AMD-3100, Nelfinavir, Efavirenz) with 30 IU IL-2 and treated with the indicated LRAs for 48 hours with the exception of AZD5582: 100 nM Ingenol 3,20 dibenzoate, 330 nM SAHA, 10 µM MS-275. For AZD5582 stimulation, cells were incubated with 100 nM AZD5582 for 1 hour and then washed to remove the compound and avoid toxicity (49), cells
were then placed back in ARV-containing media in the presence of IL-2. After 48 hours, cells were stained for viability, CD4 surface expression and intracellular expression of p24-Gag as indicated below.

**Calculation of provirus inducibility**

Percentage of inducible proviruses was determined by converting percentage of p24 positive CD4 negative cells in the CD3/CD28 or LRA stimulated condition to reactivated cells per million cultured T_{CM} and divided by the copies of either total gag per million cultured T_{CM}, total intact copies per million cultured T_{CM}, or HMW total or intact copies per million cultured T_{CM}.

**Flow Cytometry analysis**

For measuring latency reversal and HIV-1 infection by flow cytometry, cells were first stained with fixable viability dye (eFluor 450, ebioscience) followed by CD4 surface staining (S3.5, APC conjugate, Life technologies). Cells were then fixed and permeabilized as previously described (19). We define infected or reactivated cells by their CD4 downregulation and p24-Gag expression. To determine the CD4 negative p24-Gag positive gate, uninfected donor cells were used in all experiments in parallel. Flow cytometry was performed on a Becton Dickinson LSR Fortessa flow cytometer using the FACSDiva acquisition software (Becton Dickinson). FlowJo software (TreeStar) was utilized to analyze data.

**Statistics**

Wilcoxon matched-pairs signed rank test or Kruskal-Wallis test with Dunn’s post hoc multiple comparisons test was used to calculate p-values where indicated. Spearman correlation was calculated for correlations. Statistics were calculated using Prism 8 for Mac OS X software (Graphpad). Where indicated, calculated p-values were adjusted for multiple comparisons using the step-down method of Holm in SAS version 9.4.
**Blood donor information**

De-identified buffy coats were purchased from Gulf Coast Regional Blood Center. Blood donors were at least 17 years old at time of blood donation and were HIV-1 negative blood donors. Age and gender information was available.

**Acknowledgements**

We would like to thank Dr. Amanda Macedo and Dr. Rachel Resop for advice on the primary model of latency. We would also like to thank Dr. Sara Morón-López for her help on the ddPCR assays. This work was partially supported by the National Institute of Health grant R01-AI124722 to A.B. and UM1-AI126617 to A.B. and R.B.J. I.S. was supported with a fellowship by the National Institutes of Health under the Ruth L. Kirschstein National Research Service Award NIH F31 AI147814. This research has been facilitated by the services and resources provided by the District of Columbia Center for AIDS Research, an NIH funded program (AI117970), which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, NIDDK, NIMHD, NIDCR, NINR, FIC and OAR. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

**Author Contributions**

Conceptualization, I.S. and A.B.; Methodology, I.S., S.H., R.B.J., A.B.; Validation, I.S., A.B.; Formal Analysis, I.S., A.R.W.; Investigation, I.S.; Data Curation, I.S.; Visualization, I.S. and A.B.; Writing – Original Draft, I.S.; Writing – Review & Editing, I.S., S.H., A.R.W., R.B.J.,
All authors discussed the results and commented on the manuscript.

Declaration of Interests

The authors declare no competing interests.

Figure legends

**Figure 1. The TCM model can be adapted to R5 and subtype C viruses.** (A) Outline of the TCM model of latency. (B) Percentage of infected cells measured by p24 expression and CD4 downregulation by flow cytometry on days 10, 13, 17, and 19, representative donor shown. (C) Summary of the primary cell model generated with 11-12 donors per virus. (D) Analysis of the rate of viral replication, from day 10 to day 13. (E) Analysis of residual infection at day 17 after addition of ARV on day 13. (F) Percentage of cells infected on days 10 and 13, with or without addition of ARV combinations AMD-3100/ Efavirenz (EFZ)/ Nelfinavir (NEL) or Raltegravir (RAL)/ Nelfinavir (NEL). (G) Measurement of latency reversal with no cytokine or IL-2/CD3/CD28 stimulation for 48 hours, reactivated cells were measured by p24 expression and CD4 downregulation. (H) Correlation between percentage of infected cells on day 13 and reactivation on day 19 with CD3/CD28 beads, calculated using nonparametric Spearman correlation. AD8 is labelled red, MJ4 is black, and NL4-3 is blue. Circle symbol indicates female blood donor, square symbol indicates male blood donor. Wilcoxon matched-pairs signed rank test was used to calculate p-values, n=11-12 donors per virus.
Figure 2. Latently infected cells exhibit low inducibility despite maximal stimulation. (A) Total HIV-1 gag copies per million cultured T<sub>CM</sub>. The percentage of inducible proviruses was determined by dividing the CD3/CD28 stimulated reactivated cells per million cultured T<sub>CM</sub> by the total gag HIV-1 copies per million cultured T<sub>CM</sub>, separated by virus (B) or stimuli (C). (D) Total copies of intact proviruses were determined using the IPDA by digital droplet PCR. Percentage of intact inducible proviruses was determined by dividing the CD3/CD28 stimulated reactivated cells per million cultured T<sub>CM</sub> by the intact HIV-1 copies per million cultured T<sub>CM</sub>, separated by virus (E) or stimuli (F). (G) Proportions of 5’ deleted, 3’ deleted or hypermutated, and intact proviruses determined by IPDA, mean percentages of each species for each virus are reported. (H) Subset of donors assessed for deletion or hypermutation of the 3’ region in modified IPDA. (I) Average DNA shearing index shown for DNA samples, standard deviation is shown. (J) Correlation of total HIV-1 gag copies per million cultured T<sub>CM</sub> and total intact HIV-1 copies per million cultured T<sub>CM</sub>, calculated using nonparametric Spearman correlation. Dunn’s multiple comparisons test was used to calculate p-values for A, C, D and G, Wilcoxon matched-pairs signed rank test was used for B and F, n=11-12.

Figure 3. Clinically relevant LRAs are largely ineffective at reactivating intact latent proviruses. (A) A panel of LRAs were tested in their ability to reactivate latent HIV in latently infected cells generated with AD8, NL4-3 or MJ4. Reactivation was measured by p24 expression and CD4 downregulation by flow cytometry. Wilcoxon matched-pairs signed rank test was used to calculate p-values and adjusted using Holm’s step-down method. (B) Percentage of intact induced proviruses was determined by dividing the LRA-specific reactivated cells per million...
CD4 by the intact HIV-1 copies per million CD4. Dunn’s multiple comparisons test was used to calculate p-values, n=5-12 depending on LRA.

Figure 4. Isolation of HMW DNA eliminates unintegrated proviruses and reveals greater inducibility in the T<sub>CM</sub> model of latency. (A) Measurement of 2LTR circles in a single donor pre- and post-PFGE. (B) Total HIV-1 DNA copies (sum of 5’ deleted, 3’deleted/hypermutated, and intact proviruses) and intact HIV-1 DNA copies measured in samples post-PFGE.

Proportions of intact, 5’ deleted, 3’deleted/hypermutated proviruses are shown as averages of all donors in the pie chart, and individual donors for each virus: AD8 (C), MJ4 (D), and NL4-3 (E).

Correlation between pre-and post-PFGE total HIV-1 DNA copies (F) or intact HIV-1 DNA copies (G). Correlation between Day 13 infection and post-PFGE total HIV-1 DNA copies (H) or intact (I). Correlation between reactivation on day 19 with CD3/CD28 beads and post-PFGE total HIV-1 DNA (J) or intact HIV-1 DNA (K). Correlations were calculated using nonparametric Spearman correlation. AD8 is labelled red, MJ4 is labelled black, and NL4-3 is labelled blue for F-K.

Figure 5. LRAs do not reactivate majority of integrated intact proviruses in this in vitro system. Reactivation for each LRA condition measured by percentage of p24 expression and CD4 downregulation by flow cytometry, normalized to post-PFGE total (intact, 5’ deleted, 3’deleted/hypermutated) HIV-1 DNA copies (A), or post-PFGE intact HIV-1 DNA copies (B). Average reactivation per LRA and per virus (C).

References
1. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 94:13193-7.

2. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-300.

3. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9:727-8.

4. Ganor Y, Real F, Sennepin A, Dutertre CA, Prevedel L, Xu L, Tudor D, Charmeteau B, Couedel-Courteille A, Marion S, Zenak AR, Jourdain JP, Zhou Z, Schmitt A, Capron C, Eugenin EA, Cheynier R, Revol M, Cristofari S, Hosmalin A, Bomsel M. 2019. HIV-1 reservoirs in urethral macrophages of patients under suppressive antiretroviral therapy. Nat Microbiol 4:633-644.

5. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassen MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sekaly RP. 2009. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15:893-900.

6. Brenchley JM, Hill BJ, Ambrozak DR, Price DA, Guenaga FJ, Casazza JP, Kuruppu J, Yazdani J, Migueles SA, Connors M, Roederer M, Douek DC, Koup RA. 2004. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol 78:1160-8.
7. McNamara LA, Ganesh JA, Collins KL. 2012. Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-kappaB activation. J Virol 86:9337-50.

8. Wong JK, Yukl SA. 2016. Tissue reservoirs of HIV. Curr Opin HIV AIDS 11:362-70.

9. Venanzi Rullo E, Cannon L, Pinzone MR, Ceccarelli M, Nunnari G, O'Doherty U. 2019. Genetic Evidence That Naive T Cells Can Contribute Significantly to the Human Immunodeficiency Virus Intact Reservoir: Time to Re-evaluate Their Role. Clin Infect Dis 69:2236-2237.

10. Castro-Gonzalez S, Colomer-Lluch M, Serra-Moreno R. 2018. Barriers for HIV Cure: The Latent Reservoir. AIDS Res Hum Retroviruses 34:739-759.

11. Kim Y, Anderson JL, Lewin SR. 2018. Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV. Cell Host Microbe 23:14-26.

12. Spivak AM, Planelles V. 2016. HIV-1 Eradication: Early Trials (and Tribulations).

13. Bonczkowski P, De Spiegelaere W, Bosque A, White CH, Nuffel AV, Malatinkova E, Kiselinova M, Trypsteen W, Witkowski W, Vermeire J, Verhasselt B, Martins L, Woelk CH, Planelles V, Vandekerckhove L. 2014. Replication competent virus as an important source of bias in HIV latency models utilizing single round viral constructs. Retrovirology 11.

14. Bosque A, Planelles V. 2009. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 113:58-65.

15. Bosque A, Planelles V. 2011. Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells. Methods 53:54-61.
16. Larson EC, Novis CL, Martins LJ, Macedo AB, Kimball KE, Bosque A, Planelles V, Barrows LR. 2017. Mycobacterium tuberculosis reactivates latent HIV-1 in T cells in vitro. PLoS One 12:e0185162.

17. Macedo AB, Novis CL, De Assis CM, Sorensen ES, Moszczynski P, Huang S-h, Ren Y, Spivak AM, Jones RB, Planelles V, Bosque A. 2018. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents. JCI Insight 3.

18. Macedo AB, Resop RS, Martins LJ, Szaniawski MA, Sorensen ES, Spivak AM, Nixon DF, Jones RB, Planelles V, Bosque A. 2018. Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus. AIDS Res Hum Retroviruses 34:769-777.

19. Martins LJ, Bonczkowski P, Spivak AM, De Spiegelaere W, Novis CL, DePaula-Silva AB, Malatinkova E, Trypsteen W, Bosque A, Vanderkerckhove L, Planelles V. 2016. Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus. AIDS Res Hum Retroviruses 32:187-93.

20. Novis CL, Archin NM, Buzon MJ, Verdin E, Round JL, Lichterfeld M, Margolis DM, Planelles V, Bosque A. 2013. Reactivation of latent HIV-1 in central memory CD4(+) T cells through TLR-1/2 stimulation. Retrovirology 10:119.

21. Sherrill-Mix S, Lewinski MK, Famiglietti M, Bosque A, Malani N, Ocieja KE, Berry CC, Looney D, Shan L, Agosto LM, Pace MJ, Siliciano RF, O'Doherty U, Guatelli J, Planelles V, Bushman FD. 2013. HIV latency and integration site placement in five cell-based models. Retrovirology 10:90.

22. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, Greene WC, Kashuba A, Lewin SR, Margolis DM, Mau M, Ruelas D, Saleh S, Shirakawa K, Siliciano...
RF, Singhania A, Soto PC, Terry VH, Verdin E, Woelk C, Wooden S, Xing S, Planelles V. 2013. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog 9:e1003834.

23. Sunshine S, Kirchner R, Amr SS, Mansur L, Shakhbatyan R, Kim M, Bosque A, Siliciano RF, Planelles V, Hofmann O, Ho Sui S, Li JZ. 2016. HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay. J Virol 90:4511-4519.

24. White CH, Moesker B, Beliakova-Bethell N, Martins LJ, Spina CA, Margolis DM, Richman DD, Planelles V, Bosque A, Woelk CH. 2016. Transcriptomic Analysis Implicates the p53 Signaling Pathway in the Establishment of HIV-1 Latency in Central Memory CD4 T Cells in an In Vitro Model. PLoS Pathog 12:e1006026.

25. Bosque A, Nilson KA, Macedo AB, Spivak AM, Archin NM, Van Wagoner RM, Martins LJ, Novis CL, Szaniawski MA, Ireland CM, Margolis DM, Price DH, Planelles V. 2017. Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation. Cell Rep 18:1324-1334.

26. Moron-Lopez S, Telwatte S, Sarabia I, Battivelli E, Montano M, Macedo AB, Aran D, Butte AJ, Jones RB, Bosque A, Verdin E, Greene WC, Wong JK, Yukl SA. 2020. Human splice factors contribute to latent HIV infection in primary cell models and blood CD4+ T cells from ART-treated individuals. PLoS Pathog 16:e1009060.

27. Sorensen ES, Macedo AB, Resop RS, Howard JN, Nell R, Sarabia I, Newman D, Ren Y, Jones RB, Planelles V, Spivak AM, Bosque A. 2020. Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents. Antimicrob Agents Chemother 64.
28. Saayman S, Ackley A, Turner AW, Famiglietti M, Bosque A, Clemson M, Planelles V, Morris KV. 2014. An HIV-encoded antisense long noncoding RNA epigenetically regulates viral transcription. Mol Ther 22:1164-1175.

29. Bosque A, Famiglietti M, Weyrich AS, Goulston C, Planelles V. 2011. Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog 7:e1002288.

30. Hemelaar J, Gouws E, Ghys PD, Osmanov S, Isolation W-UNfH, Characterisation. 2011. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25:679-89.

31. Prodger JL, Lai J, Reynolds SJ, Keruly JC, Moore RD, Kasule J, Kityamuweesi T, Buule P, Serwadda D, Nason M, Capoferri AA, Porcella SF, Siliciano RF, Redd AD, Siliciano JD, Quinn TC. 2017. Reduced Frequency of Cells Latently Infected With Replication-Competent Human Immunodeficiency Virus-1 in Virally Suppressed Individuals Living in Rakai, Uganda. Clin Infect Dis 65:1308-1315.

32. Omondi FH, Chandrarathna S, Mujib S, Brumme CJ, Jin SW, Sudderuddin H, Miller RL, Rahimi A, Laeyendecker O, Bonner P, Yue FY, Benko E, Kovacs CM, Brockman MA, Ostrowski M, Brumme ZL. 2019. HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals. J Virol 93.

33. Sarabia I, Bosque A. 2019. HIV-1 Latency and Latency Reversal: Does Subtype Matter? Viruses 11.

34. Pierson T, Hoffman TL, Blankson J, Finzi D, Chadwick K, Margolick JB, Buck C, Siliciano JD, Doms RW, Siliciano RF. 2000. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J Virol 74:7824-33.
35. Freed EO, Englund G, Martin MA. 1995. Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol 69:3949-54.
36. Ndung’u T, Renjifo B, Essex M. 2001. Construction and analysis of an infectious human Immunodeficiency virus type 1 subtype C molecular clone. J Virol 75:4964-72.
37. Garcia JV, Miller AD. 1991. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 350:508-11.
38. Willey RL, Maldarelli F, Martin MA, Strebel K. 1992. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 66:7193-200.
39. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF. 2013. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155:540-51.
40. Massanella M, Richman DD. 2016. Measuring the latent reservoir in vivo. J Clin Invest 126:464-72.
41. Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, Fray EJ, Beg SA, Antar AAR, Jenike KM, Bertagnolli LN, Capoferri AA, Kufera JT, Timmons A, Nobles C, Gregg J, Wada N, Ho YC, Zhang H, Margolick JB, Blankson JN, Deeks SG, Bushman FD, Siliciano JD, Laird GM, Siliciano RF. 2019. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature 566:120-125.
42. Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V. 2015. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients. Antimicrob Agents Chemother 59:5984-91.
43. Pandelo Jose D, Bartholomeeusen K, da Cunha RD, Abreu CM, Ginski J, da Costa TB, Bacchi Rabay AF, Pianowski Filho LF, Dudycz LW, Ranga U, Peterlin BM, Pianowski LF, Tanuri A, Aguiar RS. 2014. Reactivation of latent HIV-1 by new semi-synthetic ingenol esters. Virology 462-463:328-39.

44. Bouchat S, Delacourt N, Kula A, Darcis G, Van Driessche B, Corazza F, Gatot JS, Melard A, Vanhulle C, Kabeya K, Pardons M, Avetand-Fenoel V, Clumeck N, De Wit S, Rohr O, Rouzioux C, Van Lint C. 2016. Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1. EMBO Mol Med 8:117-38.

45. Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L, Herbein G, De Wit S, Clumeck N, Lambotte O, Rouzioux C, Rohr O, Van Lint C. 2012. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS 26:1473-82.

46. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482-5.

47. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, McMahon J, Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin R, Procopio FA, Zeidan J, Palmer S, Odevall L, Johnstone RW, Martin BP, Sinclair E, Deeks SG, Hazuda DJ, Cameron PU, Sekaly RP, Lewin SR. 2014. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog 10:e1004473.
48. Zaikos TD, Painter MM, Sebastian Kettinger NT, Terry VH, Collins KL. 2018. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression. J Virol 92.

49. Sampey GC, Irlbeck DM, Browne EP, Kanke M, McAllister AB, Ferris RG, Brehm JH, Favre D, Routy J-P, Jones CD, Archin NM, Margolis DM, Dunham RM. 2018. The SMAC Mimetic AZD5582 is a Potent HIV Latency Reversing Agent. bioRxiv doi:10.1101/312447:312447.

50. Kuo L, Lawrence D, McDonald D, Refsland E, Bridges S, Smiley S, Tressler RL, Beaubien C, Salzwedel K. 2019. Highlights from the Fourth Biennial Strategies for an HIV Cure Meeting, 10-12 October 2018, Bethesda, MD, USA. J Virus Erad 5:50-59.

51. Lada SM, Huang K, VanBelzen DJ, Montaner LJ, O'Doherty U, Richman DD. 2018. Quantitation of Integrated HIV Provirus by Pulsed-Field Gel Electrophoresis and Droplet Digital PCR. J Clin Microbiol 56.

52. Pinzone MR, Bertuccio MP, VanBelzen DJ, Zurakowski R, O'Doherty U. 2020. Next-Generation Sequencing in a Direct Model of HIV Infection Reveals Important Parallels to and Differences from In Vivo Reservoir Dynamics. J Virol 94.

53. Pollakis G, Abebe A, Kliphuis A, Chalaby MI, Bakker M, Mengistu Y, Brouwer M, Goudsmit J, Schuitemaker H, Paxton WA. 2004. Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J Virol 78:2841-52.

54. Duenas-Decamp MJ, Peters PJ, Repik A, Musich T, Gonzalez-Perez MP, Caron C, Brown R, Ball J, Clapham PR. 2010. Variation in the biological properties of HIV-1 R5
envelopes: implications of envelope structure, transmission and pathogenesis. Future Virol 5:435-451.

55. Bruner KM, Murray AJ, Pollack RA, Soliman MG, Laskey SB, Capoferri AA, Lai J, Strain MC, Lada SM, Hoh R, Ho YC, Richman DD, Deeks SG, Siliciano JD, Siliciano RF. 2016. Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat Med 22:1043-9.

56. Imamichi H, Smith M, Adelsberger JW, Izumi T, Scrimieri F, Sherman BT, Rehm CA, Imamichi T, Pau A, Catalfamo M, Fauci AS, Lane HC. 2020. Defective HIV-1 proviruses produce viral proteins. Proc Natl Acad Sci U S A 117:3704-3710.

57. Pollack RA, Jones RB, Pertea M, Bruner KM, Martin AR, Thomas AS, Capoferri AA, Beg SA, Huang SH, Karandish S, Hao H, Halper-Stromberg E, Yong PC, Kovacs C, Benko E, Siliciano RF, Ho YC. 2017. Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. Cell Host Microbe 21:494-506 e4.

58. Harris RS, Liddament MT. 2004. Retroviral restriction by APOBEC proteins. Nat Rev Immunol 4:868-77.

59. Shindo K, Takaori-Kondo A, Kobayashi M, Abudu A, Fukunaga K, Uchiyama T. 2003. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J Biol Chem 278:44412-6.

60. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-50.
61. Resop RS, Fromentin R, Newman D, Rigsby H, Dubrovsky L, Bukrinsky M, Chomont N, Bosque A. 2020. Fingolimod inhibits multiple stages of the HIV-1 life cycle. PLoS Pathog 16:e1008679.

62. Bachu M, Yalla S, Asokan M, Verma A, Neogi U, Sharma S, Murali RV, Mukthey AB, Bhatt R, Chatterjee S, Rajan RE, Cheedarla N, Yadavalli VS, Mahadevan A, Shankar SK, Rajagopalan N, Shet A, Saravanan S, Balakrishnan P, Solomon S, Vajpayee M, Satish KS, Kundu TK, Jeang KT, Ranga U. 2012. Multiple NF-kappaB sites in HIV-1 subtype C long terminal repeat confer superior magnitude of transcription and thereby the enhanced viral predominance. J Biol Chem 287:44714-35.

63. Qu D, Li C, Sang F, Li Q, Jiang ZQ, Xu LR, Guo HJ, Zhang C, Wang JH. 2016. The variances of Sp1 and NF-kappaB elements correlate with the greater capacity of Chinese HIV-1 B‘-LTR for driving gene expression. Sci Rep 6:34532.

64. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, Johnstone RW. 2001. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 98:10833-8.

65. Kulpa DA, Talla A, Brehm JH, Ribeiro SP, Yuan S, Bebin-Blackwell AG, Miller M, Barnard R, Deeks SG, Hazuda D, Chomont N, Sekaly RP. 2019. Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4(+) T Cells. J Virol 93.
Pardons M, Fromentin R, Pagliuzza A, Routy JP, Chomont N. 2019. Latency-Reversing Agents Induce Differential Responses in Distinct Memory CD4 T Cell Subsets in Individuals on Antiretroviral Therapy. Cell Rep 29:2783-2795 e5.

Grau-Exposito J, Luque-Ballesteros L, Navarro J, Curran A, Burgos J, Ribera E, Torrella A, Planas B, Badia R, Martin-Castillo M, Fernandez-Sojo J, Genesca M, Falco V, Buzon MJ. 2019. Latency Reversal Agents Affect Differently the Latent Reservoir Present in Distinct CD4+ T Subpopulations. PLoS Pathog 15:e1007991.

Kwon KJ, Timmons AE, Sengupta S, Simonetti FR, Zhang H, Hoh R, Deeks SG, Siliciano JD, Siliciano RF. 2020. Different human resting memory CD4(+) T cell subsets show similar low inducibility of latent HIV-1 proviruses. Sci Transl Med 12.

Martin AR, Bender AM, Hackman J, Kwon KJ, Lynch BA, Bruno D, Martens C, Beg S, Florman SS, Desai N, Segev D, Laird GM, Siliciano JD, Quinn TC, Tobian AAR, Durand CM, Siliciano RF, Redd AD, Team HiAS. 2020. Similar frequency and inducibility of intact HIV-1 proviruses in blood and lymph nodes. J Infect Dis doi:10.1093/infdis/jiaa736.

Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59:284-91.

Huang SH, Ren Y, Thomas AS, Chan D, Mueller S, Ward AR, Patel S, Bollard CM, Cruz CR, Karandish S, Truong R, Macedo AB, Bosque A, Kovacs C, Benko E, Piechocka-Trocha A, Wong H, Jeng E, Nixon DF, Ho YC, Siliciano RF, Walker BD, Jones RB. 2018. Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. J Clin Invest 128:876-889.
TABLE 1 Primer and Probe sequences for ddPCR assays.

| Primer/Probe name | Sequence | Reference |
|-------------------|----------|-----------|
| RPP30 F           | GATTTGGACCTGCAGGAGCG | Huang et al, 2018 |
| RPP30 R           | GCGGCTGCTCCCAAAGTG | Huang et al, 2018 |
| RPP30 probe       | VIC-CTGAAACTGAAGGTCTCT-MGBNFQ | Huang et al, 2018 |
| HIV-gag NL4-3 F   | TCTCGACGCAAGGAGCTCG | This paper |
| HIV-gag NL4.3 R   | TACCACGCTCTCCACC | This paper |
| HIV-gag MJ4 F     | TCTCGACGCAAGGACTCG | This paper |
| HIV-gag MJ4 R     | TATTCGACGCTCTCCACC | This paper |
| RPP30 Shear 1 F   | CCATTTGCTCTCCATTGCG | This paper |
| RPP30 Shear 1 R   | CATGCAAAGGAGGAGCG | This paper |
| RPP30 Shear 1 Probe | VIC-CTGACCTGCTGCTCTCG | This paper |
| RPP30 Shear 2 F   | GATTTGGACCTGCAGGAGCG | This paper |
| RPP30 Shear 2 R   | GCGGCTGCTCCCAAAGTG | This paper |
| IPDA SubtypeB Psi F | CAGGGACTGGGCTGCAGAG | Bruner et al, 2019 |
| IPDA SubtypeB Psi R | GCCAACACTCTCTCCATTAC | Bruner et al, 2019 |
| IPDA SubtypeB Psi Probe | VIC-CTGACGCTCTGGTCTCAGCG | Bruner et al, 2019 |
| IPDA SubtypeB Env F | AGTTGGGAGCAGAGAAAGAC | Bruner et al, 2019 |
| IPDA SubtypeB Env R | GTCTGGCCCTGCTACGGTAC | Bruner et al, 2019 |
| IPDA SubtypeB Env Probe | VIC-CTGACGCTCTGGTCTCAGCG | Bruner et al, 2019 |
| Env Hypermutation Probe non-fluorescent | /56-FAM/CTGGAGCT/CTTGGGAGCC/3IABkFQ/ | Bruner et al, 2019 |
| Env Hypermutation Probe fluorescent | /56-FAM/CTTAGGTT/TTCGTAGGAGCC/3IABkFQ/ | Bruner et al, 2019 |
| IPDA SubtypeC Psi F | GGACTGGGCTGCAGAGAGTG | This paper |
| IPDA SubtypeC Psi R | GACCACTCTCCATTACGC | This paper |
| IPDA SubtypeC Psi Probe | /56-FAM/TGGGTGCAGTGAAGCC/3IABkFQ/ | This paper |
| IPDA SubtypeC Env F | AGTTGGGAGCAGAGAAAGAC | This paper |
| IPDA SubtypeC Env R | GTCTGGCCCTGCTACGGTAC | This paper |
| IPDA SubtypeC Env Probe | /5HEX/CTTGGGTT/CTTGGGAGCC/3IABkFQ/ | This paper |
